PAKZYOS Trademark

Trademark Overview


On Tuesday, May 11, 2021, a trademark application was filed for PAKZYOS with the United States Patent and Trademark Office. The USPTO has given the PAKZYOS trademark a serial number of 90702301. The federal status of this trademark filing is FOURTH EXTENSION - GRANTED as of Wednesday, October 23, 2024. This trademark is owned by MyoKardia, Inc.. The PAKZYOS trademark is filed in the Pharmaceutical Products category with the following description:

Pharmaceutical preparations for human use for the treatment and prevention of obesity, incontinence, cardiovascular diseases, central nervous system diseases and disorders, metabolic disorders, stroke, cancer, inflammation and inflammatory diseases, respiratory and infectious diseases, auto-immune diseases, solid organ transplant rejection, beta thalassemia and myelodysplastic syndromes, myeloproliferative diseases, myelofibrosis, leukemia, lymphoma, multiple myeloma, autoinflammatory disease, blood disease, tumors, multiple sclerosis, ulcerative colitis, arthritis, and musculoskeletal and skin diseases; Pharmaceutical preparations for human use, namely, antibiotics, anti-fungals, anti-virals, immunosuppressants, pharmaceutical antibodies, immunotherapies for the treatment of cancer, cytokine inhibitory drugs; Pharmaceutical preparations for human use that modulate the immune system; Pharmaceutical and biological preparations for human use for immunotherapy, namely T Cell therapy; Phar...
pakzyos

General Information


Serial Number90702301
Word MarkPAKZYOS
Filing DateTuesday, May 11, 2021
Status733 - FOURTH EXTENSION - GRANTED
Status DateWednesday, October 23, 2024
Registration Number0000000
Registration DateNOT AVAILABLE
Mark Drawing4 - Illustration: Drawing with word(s) / letter(s) / number(s) in Block form
Published for Opposition DateTuesday, August 30, 2022

Trademark Statements


Goods and ServicesPharmaceutical preparations for human use for the treatment and prevention of obesity, incontinence, cardiovascular diseases, central nervous system diseases and disorders, metabolic disorders, stroke, cancer, inflammation and inflammatory diseases, respiratory and infectious diseases, auto-immune diseases, solid organ transplant rejection, beta thalassemia and myelodysplastic syndromes, myeloproliferative diseases, myelofibrosis, leukemia, lymphoma, multiple myeloma, autoinflammatory disease, blood disease, tumors, multiple sclerosis, ulcerative colitis, arthritis, and musculoskeletal and skin diseases; Pharmaceutical preparations for human use, namely, antibiotics, anti-fungals, anti-virals, immunosuppressants, pharmaceutical antibodies, immunotherapies for the treatment of cancer, cytokine inhibitory drugs; Pharmaceutical preparations for human use that modulate the immune system; Pharmaceutical and biological preparations for human use for immunotherapy, namely T Cell therapy; Pharmaceutical preparations for human use, namely, stem cells for medical or clinical use; Pharmaceutical preparations for treatment or prevention of covid-19, coronavirus disease, and respiratory diseases and disorders; antivirals for treatment or prevention of covid-19, coronavirus disease, and respiratory diseases and disorders; monoclonal antibodies

Classification Information


International Class005 - Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides.
US Class Codes005, 006, 018, 044, 046, 051, 052
Class Status Code6 - Active
Class Status DateTuesday, August 10, 2021
Primary Code005
First Use Anywhere DateNOT AVAILABLE
First Use In Commerce DateNOT AVAILABLE

Trademark Owner History


Party NameMyoKardia, Inc.
Party Type20 - Owner at Publication
Legal Entity Type03 - Corporation
AddressBrisbane, CA 94005

Party NameMyoKardia, Inc.
Party Type10 - Original Applicant
Legal Entity Type03 - Corporation
AddressBrisbane, CA 94005

Trademark Events


Event DateEvent Description
Tuesday, January 18, 2022ASSIGNED TO EXAMINER
Friday, May 14, 2021NEW APPLICATION ENTERED
Tuesday, August 10, 2021NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Tuesday, January 25, 2022NOTIFICATION OF NON-FINAL ACTION E-MAILED
Tuesday, January 25, 2022NON-FINAL ACTION WRITTEN
Tuesday, January 25, 2022NON-FINAL ACTION E-MAILED
Monday, July 25, 2022APPROVED FOR PUB - PRINCIPAL REGISTER
Monday, July 18, 2022TEAS RESPONSE TO OFFICE ACTION RECEIVED
Monday, July 18, 2022CORRESPONDENCE RECEIVED IN LAW OFFICE
Monday, July 18, 2022TEAS/EMAIL CORRESPONDENCE ENTERED
Wednesday, August 10, 2022NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Tuesday, August 30, 2022PUBLISHED FOR OPPOSITION
Tuesday, August 30, 2022OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Tuesday, October 25, 2022NOA E-MAILED - SOU REQUIRED FROM APPLICANT
Thursday, April 6, 2023SOU TEAS EXTENSION RECEIVED
Thursday, April 6, 2023SOU EXTENSION 1 FILED
Thursday, April 6, 2023SOU EXTENSION 1 GRANTED
Saturday, April 8, 2023NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Friday, October 6, 2023SOU TEAS EXTENSION RECEIVED
Friday, October 6, 2023SOU EXTENSION 2 FILED
Friday, October 6, 2023SOU EXTENSION 2 GRANTED
Thursday, March 14, 2024SOU EXTENSION 3 GRANTED
Thursday, March 14, 2024SOU TEAS EXTENSION RECEIVED
Thursday, March 14, 2024SOU EXTENSION 3 FILED
Tuesday, October 10, 2023NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Friday, March 15, 2024NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Wednesday, October 23, 2024SOU TEAS EXTENSION RECEIVED
Wednesday, October 23, 2024NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Wednesday, October 23, 2024SOU EXTENSION 4 GRANTED
Wednesday, October 23, 2024SOU EXTENSION 4 FILED